Observed arrival · 2026-11-05
Drugmarker’s variant-to-therapy evidence dossier
A research workflow for turning variant files into reviewable, cited molecular evidence reports for tumor-board preparation.
○Open
⊠Login
$Paid
†Ads
✦Pretty
●Pro
◎Niche
◉Human
⚑Risk
ƒJS
- For
- Molecular tumor-board and variant-review teams
- Worth noticing
- The synthetic example names GRCh38 and VEP 116, and shows EGFR L858R separately from T790M resistance context.
Field notes
The page identifies CIViC, ClinVar, ClinicalTrials.gov, VEP 116, and gnomAD as parts of its evidence layer, and shows an illustrative synthetic case, DM-2026-008. Its workflow description keeps sensitivity, resistance, and unknown signals distinct, with reportable, incidental, and pending decisions retained in a versioned report. The site says pilot onboarding is manually reviewed and labels the tool research-use-only.
Observed signals
Read the marks
Editorial observations of this landing page, not a rating.
○OpenPublic substance visible
⊠LoginAccess appeared gated
✦PrettyNotable craft visible
●ProPolished or operationally mature
◎NicheUnusually specific use
One card from the complete issue